Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | ACSS2 | Q9NR19 | 7/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13490310 | 1.00 | NPC1 (0.50) | NPC1RAB9AACSS2ACHECHRNA7 | |
| SCHEMBL3223316 | 0.91 | NPC1 (0.49) | NPC1RAB9AACSS2ACHECHRNA7 | |
| SCHEMBL14192263 | 0.91 | NPC1 (0.49) | NPC1RAB9AACSS2ACHECHRNA7 | |
| SCHEMBL13490428 | 0.91 | NPC1 (0.49) | NPC1RAB9AACSS2ACHECHRNA7 | |
| SCHEMBL3213313 | 0.90 | NPC1 (0.47) | NPC1RAB9AACSS2ACHECHRNA7 | |
| SCHEMBL13490317 | 0.90 | NPC1 (0.47) | NPC1RAB9AACSS2ACHECHRNA7 | |
| SCHEMBL3220241 | 0.90 | NPC1 (0.47) | NPC1RAB9AACSS2ACHECHRNA7 | |
| SCHEMBL13490328 | 0.89 | NPC1 (0.53) | NPC1RAB9AACHECHRNA7TP53 | |
| SCHEMBL14192807 | 0.89 | NPC1 (0.53) | NPC1RAB9AACHECHRNA7TP53 | |
| SCHEMBL3219354 | 0.89 | NPC1 (0.53) | NPC1RAB9AACHECHRNA7TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029615-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2010-02-04 | — | — | US | disclosed |
| EP-2121626-A1 | BENZIMIDAZOLE DERIVATIVES | Pfizer Products Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008075196-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029615-A1 | BENZIMIDAZOLE DERIVATIVES | ACIN1, HAT1, CCNE1 | NPC1 3250/4885RAB9A 1662/4885ACSS2 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.